Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study.


Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
05 01 2022
Historique:
received: 02 12 2020
pubmed: 31 3 2021
medline: 1 4 2022
entrez: 30 3 2021
Statut: ppublish

Résumé

Prediction of endoscopic postoperative recurrence (POR) and prophylactic treatment based on clinical risk profile have thus far been inconclusive. This study aimed to examine the association between clinical risk profile and the development of endoscopic POR in a Crohn's disease population without postoperative treatment and to identify individual risk factors of endoscopic POR. Medical records of 142 patients with Crohn's disease during follow-up after ileocecal or ileocolonic resection without prophylactic treatment at 3 referral centers were reviewed. Endoscopic POR was defined as a modified Rutgeerts score ≥i2b. Clinical risk profiles were distilled from current guidelines. Both uni- and multivariate logistic regression analysis were used to assess the relationship between risk profiles and endoscopic POR. Endoscopic POR was observed in 68 out of 142 (47.9%) patients. Active smoking postsurgery (odds ratio [OR], 3.01; 95% confidence interval [CI], 1.24-7.34; P = 0.02), a Montreal classification of A3 (OR, 3.05; 95% CI, 1.07-8.69; P = 0.04), and previous bowel resections (OR, 2.58; 95% CI, 1.07-6.22; P = 0.03) were significantly associated with endoscopic POR. No significant association was observed between endoscopic POR and any guideline defined as a high-/low-risk profile. However, patients with a combination of any 3 or more European Crohns & Colitis Organisation- (OR, 4.87; 95% CI, 1.30-18.29; P = 0.02) or British Society of Gastroenterology-defined (OR 3.16; 95% CI, 1.05-9.49; P = 0.04) risk factors showed increased odds of developing endoscopic POR. Our results suggest that patients with a combination of any 3 or more European Crohns & Colitis Organisation- or British Society of Gastroenterology-defined risk factors would probably benefit from immediate prophylactic treatment.

Sections du résumé

BACKGROUND
Prediction of endoscopic postoperative recurrence (POR) and prophylactic treatment based on clinical risk profile have thus far been inconclusive. This study aimed to examine the association between clinical risk profile and the development of endoscopic POR in a Crohn's disease population without postoperative treatment and to identify individual risk factors of endoscopic POR.
METHODS
Medical records of 142 patients with Crohn's disease during follow-up after ileocecal or ileocolonic resection without prophylactic treatment at 3 referral centers were reviewed. Endoscopic POR was defined as a modified Rutgeerts score ≥i2b. Clinical risk profiles were distilled from current guidelines. Both uni- and multivariate logistic regression analysis were used to assess the relationship between risk profiles and endoscopic POR.
RESULTS
Endoscopic POR was observed in 68 out of 142 (47.9%) patients. Active smoking postsurgery (odds ratio [OR], 3.01; 95% confidence interval [CI], 1.24-7.34; P = 0.02), a Montreal classification of A3 (OR, 3.05; 95% CI, 1.07-8.69; P = 0.04), and previous bowel resections (OR, 2.58; 95% CI, 1.07-6.22; P = 0.03) were significantly associated with endoscopic POR. No significant association was observed between endoscopic POR and any guideline defined as a high-/low-risk profile. However, patients with a combination of any 3 or more European Crohns & Colitis Organisation- (OR, 4.87; 95% CI, 1.30-18.29; P = 0.02) or British Society of Gastroenterology-defined (OR 3.16; 95% CI, 1.05-9.49; P = 0.04) risk factors showed increased odds of developing endoscopic POR.
CONCLUSIONS
Our results suggest that patients with a combination of any 3 or more European Crohns & Colitis Organisation- or British Society of Gastroenterology-defined risk factors would probably benefit from immediate prophylactic treatment.

Identifiants

pubmed: 33783507
pii: 6203395
doi: 10.1093/ibd/izab044
pmc: PMC8730683
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Informations de copyright

© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Références

Gastroenterology. 2008 Nov;135(5):1500-9
pubmed: 18823987
Ann Surg. 2021 Mar 1;273(3):557-563
pubmed: 31188225
Gastroenterology. 2005 Apr;128(4):856-61
pubmed: 15825069
Gastroenterology. 2013 Nov;145(5):996-1006
pubmed: 23896172
Gut. 1992 Mar;33(3):331-5
pubmed: 1568651
Acta Chir Scand Suppl. 1979;490:1-84
pubmed: 293116
Gastroenterology. 2017 Jan;152(1):271-275
pubmed: 27840074
Inflamm Bowel Dis. 2020 Oct 23;26(11):1691-1699
pubmed: 31879766
Ann Surg. 1984 Mar;199(3):340-7
pubmed: 6703794
Ann Transl Med. 2016 Jan;4(2):30
pubmed: 26889483
World J Surg. 1998 Apr;22(4):364-9
pubmed: 9523518
Br J Surg. 2017 Nov;104(12):1713-1722
pubmed: 28745410
Am J Gastroenterol. 2008 Jan;103(1):196-205
pubmed: 17900320
Gastroenterology. 2017 Jan;152(1):277-295.e3
pubmed: 27840073
Gastroenterol Hepatol (N Y). 2017 Nov;13(11):651-658
pubmed: 29230144
Minerva Gastroenterol Dietol. 2011 Dec;57(4):335-44
pubmed: 22105722
Ann Surg. 2000 Jan;231(1):38-45
pubmed: 10636100
Gut. 1984 Jun;25(6):665-72
pubmed: 6735250
Mediterr J Hematol Infect Dis. 2011;3(1):e2011028
pubmed: 21869914
J Crohns Colitis. 2017 Feb;11(2):135-149
pubmed: 27660342
Am J Gastroenterol. 2010 Feb;105(2):289-97
pubmed: 19861953
Inflamm Bowel Dis. 2014 Sep;20(9):1548-54
pubmed: 25036758
Frontline Gastroenterol. 2017 Jul;8(3):203-209
pubmed: 28839910
Am J Gastroenterol. 2009 Feb;104(2):465-83; quiz 464, 484
pubmed: 19174807
Dis Colon Rectum. 2007 Oct;50(10):1674-87
pubmed: 17682822
Gut. 2011 Apr;60(4):553-62
pubmed: 21115545
World J Gastroenterol. 2005 Jul 14;11(26):3971-9
pubmed: 15996018
Inflamm Bowel Dis. 2009 Oct;15(10):1508-14
pubmed: 19322901
Gastroenterology. 2016 Jun;150(7):1568-1578
pubmed: 26946343
Dis Colon Rectum. 2008 Aug;51(8):1211-6
pubmed: 18536967
Dis Colon Rectum. 2013 Jul;56(7):881-7
pubmed: 23739195
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
J Crohns Colitis. 2015 Mar;9(3):293-301
pubmed: 25572276
Am J Gastroenterol. 2000 May;95(5):1139-46
pubmed: 10811318
Clin Exp Gastroenterol. 2016 Aug 08;9:237-48
pubmed: 27540307
Int J Colorectal Dis. 2008 Dec;23(12):1213-21
pubmed: 18762954
Gastroenterology. 1990 Oct;99(4):956-63
pubmed: 2394349

Auteurs

Vincent Joustra (V)

Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, AGEM University of Amsterdam, Amsterdam, the Netherlands.

Marjolijn Duijvestein (M)

Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, AGEM University of Amsterdam, Amsterdam, the Netherlands.

Aart Mookhoek (A)

Department of Pathology, VU University Medical Centre, Amsterdam, the Netherlands.

Willem Bemelman (W)

Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Christianne Buskens (C)

Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.

Matic Koželj (M)

Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Gregor Novak (G)

Department of Gastroenterology, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Pieter Hindryckx (P)

Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium.

Nahid Mostafavi (N)

Biostatistical Unit, Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Geert D'Haens (G)

Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, AGEM University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH